48574 Federal Register / Vol. 74, No. 183 / Wednesday, September 23, 2009 / Notices 

used. The reduced dimensional data set 

is visualized in three dimensions using 

these novel algorithms. These visualized 

algorithms derive the first three 

principal components from Fisher’s 

matrix and project the multidimensional 

data into three dimensional gene 

expression data space. Exploration of 

the reduced dimensional data set allows 

for the identification of discriminant 

genes that are either assembled into a 

predictive neural network, and/ or 

selected for functional studies. These 

approaches have proved useful in recent 

studies conducted by Dr. HilakiviClarke (Georgetown University, 

Lombardi Cancer Center) in identifying 

genes affected by timing of dietary 

exposures on breast cancer risk and are 

the preferred approaches for this study. 

Georgetown University, Lombardi 

Cancer Research Center Animal Core 

Facility has an AAALAC (Association 

for Assessment and Accreditation of 

Laboratory Animal Care) accredited 

animal facility where the animals can be 

housed. Georgetown can provide the 

software, hardware, and sophisticated, 

statistically principled data mining 

tools. In addition, Georgetown 

University is already collaborating in an 

on-going women study in Finland 

measuring hormone and adipokine 

levels from blood samples. 

This is a sole source award to 

Lombardi Comprehensive Cancer Center 

and Department of Oncology, 

Georgetown University, Washington, 

DC. 

II. Award Information/Funds Available 

Awards are made under the 

authorization of section 301 of the 

Public Health Service Act (PHS Act) (42 

U.S.C. 241), as amended, and under 

Federal regulations at 42 CFR part 52 

and 45 CFR parts 74 and 92. 

A. Award Amount 

The total amount CVM expects to 

award is $100,400 in the first year and 

$104,400 in the second year for a total 

award of $204,800; total award amount 

includes direct and indirect costs. 

B. Length of Support 

The project period will be from 

September 2009 to August 31, 2011. The 

first budget period will be from 

September 2009 to August 31, 2010. 

The second year award will depend 

on the availability of funds and 

recipient approved performance. 

III. Paper Application, Registration, 

and Submission Information 

To submit a paper application in 

response to this FOA, applicants should 

first review the full announcement 

located at http://www.fda.gpo/cvm. 

Persons interested in applying for a 

grant may obtain application forms and 

instructions at http://grants.nih.gov/ 

grants/forms.htm. For all paper 

application submissions, the following 

steps are required: 

• Step 1: Obtain a Dun and Bradstreet 

(DUNS) Number 

• Step 2: Register With Central 

Contractor Registration (CCR) 

• Step 3: Register With Electronic 

Research Administration (eRA) 

Commons 

Steps 1 (DUNS Number) and 2 (CCR), 

in detail, can be found at http:// 

www07.grants.gov/applicants/ 

organization_registration.jsp. Step 3 

(eRA Commons), in detail, can be found 

at https://commons.era.nih.gov/ 

commons/registration/registration

Instructions.jsp. 

After you have followed these steps, 

submit paper applications to the Grants 

Management Contact at the following 

address: 

Gladys M. Bohler, Division of 

Acquisition Support and Grants (HFA– 

500), Food and Drug Administration, 

5630 Fishers Lane, rm. 2105, Rockville, 

MD 20857, 301–827–7168, FAX: 301– 

827–7101, e-mail: 

gladys.bohler@fda.hhs.gov. 

Dated: September 17, 2009. 

David Horowitz, 

Assistant Commissioner for Policy. 

[FR Doc. E9–22848 Filed 9–22–09; 8:45 am] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Dental & 

Craniofacial Research; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Dental and Craniofacial Research Special 

Emphasis Panel; Review of R34 Clinical Trial 

Pilot Applications PAR–08–195 and R01 PA– 

07–070 Applications. 

Date: October 30, 2009. 

Time: 10:30 a.m. to 1:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, One 

Democracy Plaza, 6701 Democracy 

Boulevard, Bethesda, MD 20892, (Telephone 

Conference Call). 

Contact Person: Rebecca Wagenaar Miller, 

PhD, Scientific Review Officer, Scientific 

Review Branch, National Inst of Dental & 

Craniofacial Research, National Institutes of 

Health, 6701 Democracy, Rm 666, Bethesda, 

MD 20892, 301–594–0652, 

rwagenaa@mail.nih.gov. 

Catalogue of Federal Domestic Assistance 

Program Nos. 93.121, Oral Diseases and 

Disorders Research, National Institutes of 

Health, HHS) 

Dated: September 16, 2009. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E9–22969 Filed 9–22–09; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Microbiology, 

Infectious Diseases and AIDS Initial Review 

Group; Microbiology and Infectious Diseases 

Research Committee. 

Date: October 6, 2009. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Legacy, 1775 Rockville Pike, 

Rockville, MD 20852. 

Contact Person: Michelle M. Timmerman, 

PhD, Scientific Review Officer, Scientific 

Review Program, DEA/NIAID/NIH/DHHS, 

Room 2217, 6700B Rockledge Drive, MSC– 

7616, Bethesda, MD 20892–7616. 301–451– 

4573. timmermanm@niaid.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

mstockstill on DSKH9S0YB1PROD with NOTICES